MACK stock forecast
Our latest prediction for Merrimack Pharmaceuticals, Inc.'s stock price was made on the July 16, 2019 when the stock price was at 5.49$.
In the short term (2weeks), MACK's stock price should outperform the market by 3.41%. During that period the price should oscillate between -6.73% and +9.98%.
In the medium term (3months), MACK's stock price should outperform the market by 2.82%. During that period the price should oscillate between -17.12% and +26.40%.Get email alerts
Create a solid portfolio with MACK
About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
At the moment the company generates 144M USD in revenues.
On its last earning announcement, the company reported a loss of -0.50$ per share.
The book value per share is 4.67$
Three months stock forecastJuly 16, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|